Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy

The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC

Inclusion Criteria:

• Radiologically confirmed brain metastases from Non Small Cell Lung Cancer
• No symptoms due to brain metastases
• No previous radiotherapy treatment for the Brain metastases

Exclusion Criteria:

• No prior chemotherapy
• No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
• Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)